QuidelOrtho (NASDAQ:QDEL) Stock Price Down 3.4% – What’s Next?

QuidelOrtho Corporation (NASDAQ:QDEL)’s stock price dropped 3.4% during trading on Friday . The company traded as low as $14.19 and last traded at $14.35. Approximately 111,478 shares were traded during mid-day trading, a decline of 94% from the average daily volume of 1,761,439 shares. The stock had previously closed at $14.85.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on QDEL shares. UBS Group reissued a “neutral” rating and set a $12.00 price target on shares of QuidelOrtho in a report on Thursday, May 7th. Jefferies Financial Group reissued a “hold” rating on shares of QuidelOrtho in a report on Monday, June 29th. JPMorgan Chase & Co. boosted their price target on QuidelOrtho from $11.00 to $12.00 and gave the company an “underweight” rating in a research note on Wednesday, July 1st. Wall Street Zen raised shares of QuidelOrtho from a “sell” rating to a “hold” rating in a research report on Sunday, June 28th. Finally, Zacks Research cut shares of QuidelOrtho from a “hold” rating to a “strong sell” rating in a research note on Wednesday, August 12th. Three investment analysts have rated the stock with a Hold rating and three have issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Reduce” and an average target price of $13.62.

QuidelOrtho Price Performance

The company has a debt-to-equity ratio of 1.43, a quick ratio of 0.76 and a current ratio of 1.39. The company has a market cap of $1.05 billion, a P/E ratio of -1.00 and a beta of 0.68. The firm’s fifty day moving average is $15.81 and its two-hundred day moving average is $16.53.

QuidelOrtho (NASDAQ:QDEL) last announced its quarterly earnings data on Thursday, August 6th. The company reported $0.13 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.18. The business had revenue of $630.90 million during the quarter, compared to analyst estimates of $618.72 million. QuidelOrtho had a negative net margin of 39.20% and a positive return on equity of 4.88%. The company’s revenue was up 2.8% on a year-over-year basis. During the same period last year, the firm posted $0.12 EPS. QuidelOrtho has set its FY 2026 guidance at 0.650-0.900 EPS. As a group, analysts anticipate that QuidelOrtho Corporation will post 0.75 earnings per share for the current fiscal year.

Institutional Trading of QuidelOrtho

Institutional investors have recently bought and sold shares of the stock. T. Rowe Price Investment Management Inc. raised its stake in shares of QuidelOrtho by 7.4% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 11,832,098 shares of the company’s stock valued at $337,925,000 after acquiring an additional 819,908 shares during the period. BlackRock Inc. purchased a new stake in QuidelOrtho in the 2nd quarter worth about $196,212,000. Newtyn Management LLC lifted its stake in QuidelOrtho by 45.3% in the second quarter. Newtyn Management LLC now owns 6,625,000 shares of the company’s stock worth $116,037,000 after purchasing an additional 2,066,528 shares during the last quarter. Invesco Ltd. boosted its position in shares of QuidelOrtho by 19.4% during the fourth quarter. Invesco Ltd. now owns 3,470,656 shares of the company’s stock valued at $99,122,000 after buying an additional 563,893 shares during the period. Finally, Dimensional Fund Advisors LP boosted its position in shares of QuidelOrtho by 7.5% during the first quarter. Dimensional Fund Advisors LP now owns 3,048,768 shares of the company’s stock valued at $50,085,000 after buying an additional 212,481 shares during the period. 99.00% of the stock is currently owned by institutional investors.

About QuidelOrtho

QuidelOrtho is a global diagnostics company formed through the merger of Quidel Corporation and Ortho Clinical Diagnostics. The combined entity develops, manufactures and markets a broad portfolio of rapid and high-throughput diagnostic solutions across immunoassay, molecular diagnostics and transfusion medicine. Its offerings span point-of-care platforms for acute care testing as well as large-scale automated systems designed for clinical laboratories and blood banks.

The company’s product range includes rapid antigen and antibody tests for infectious diseases, molecular assays utilizing nucleic acid amplification technology, and integrated immunodiagnostic analyzers.